|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-3-22
|
|
pubmed:abstractText |
Gene-targeted mice have recently revealed a role for lymphocytes and interferon-gamma (IFNgamma) in conferring protection against cancer, but the mechanisms remain unclear. Here, we have characterized a successful primary antitumor immune response initiated by naive CD4+ T cells. Major histocompatibility complex class II (MHC-II)-negative myeloma cells injected subcutaneously into syngeneic mice were surrounded within 3 days by macrophages that captured tumor antigens. Within 6 days, naive myeloma-specific CD4+ T cells became activated in draining lymph nodes and subsequently migrated to the incipient tumor site. Upon recognition of tumor-derived antigenic peptides presented on MHC-II by macrophages, the myeloma-specific CD4+ T cells were reactivated and started to secrete cytokines. T cell-derived IFNgamma activated macrophages in close proximity to the tumor cells. Tumor cell growth was completely inhibited by such locally activated macrophages. These data indicate a mechanism for immunosurveillance of MHC-II-negative cancer cells by tumor-specific CD4+ T cells through collaboration with macrophages.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1074-7613
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
371-83
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15780993-Animals,
pubmed-meshheading:15780993-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15780993-Cell Line, Tumor,
pubmed-meshheading:15780993-Collagen,
pubmed-meshheading:15780993-Drug Combinations,
pubmed-meshheading:15780993-Drug Therapy,
pubmed-meshheading:15780993-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15780993-Flow Cytometry,
pubmed-meshheading:15780993-Histocompatibility Antigens Class II,
pubmed-meshheading:15780993-Immunohistochemistry,
pubmed-meshheading:15780993-Immunologic Surveillance,
pubmed-meshheading:15780993-Interferon-gamma,
pubmed-meshheading:15780993-Laminin,
pubmed-meshheading:15780993-Lymphocyte Activation,
pubmed-meshheading:15780993-Macrophages,
pubmed-meshheading:15780993-Mice,
pubmed-meshheading:15780993-Mice, SCID,
pubmed-meshheading:15780993-Mice, Transgenic,
pubmed-meshheading:15780993-Multiple Myeloma,
pubmed-meshheading:15780993-Neoplasm Transplantation,
pubmed-meshheading:15780993-Proteoglycans,
pubmed-meshheading:15780993-Receptors, Antigen, T-Cell
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Primary antitumor immune response mediated by CD4+ T cells.
|
|
pubmed:affiliation |
Institute of Immunology, University of Oslo, Rikshospitalet and Rikshospitalet University Hospital, 0027 Oslo, Norway. alexandre.corthay@medisin.uio.no
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
